Fig. 1

Flow chart of patient enrollment. Adults presenting with new asymptomatic venous thromboembolism (VTE), deep vein thrombosis (DVT), or pulmonary thromboembolism (PE) during systemic chemotherapy after the histological diagnosis of gastrointestinal cancer were eligible to participate in the study. The primary study endpoint (safety) was evaluated in patients who received the study drug at least once